Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SYK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Kinase | SYK Active Kinase Domain / Mutant Protein. Active & Inactive forms, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View SYK Products |
| Gene Delivery | SYK ORF Lentivirus. Full-length ORF for stable cell line construction. High titer, Puromycin selection marker. | View SYK Products |
| Benchmark Ab | Anti-SYK Monoclonal Antibody. Recombinant positive control for western blot, IP, and IHC. Sequence Verified. | View SYK Products |
| Validator | SYK siRNA Set. Three unique target sequences for knockdown verification and specificity checks. | View SYK Products |
| Related Target A | BTK (Bruton's Tyrosine Kinase). Synergistic BCR pathway target for hematological malignancies; critical for selectivity counter-screening. | View BTK Products |
| Related Target B | ZAP70. Closely related kinase family member for selectivity counter-screening. | View ZAP70 Products |
| Related Target C | PIK3CD (PI3Kδ Catalytic Subunit). Parallel survival pathway in B cells; essential for combination therapy mechanism studies. | View PIK3CD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (vs ZAP70/BTK) | High-purity human SYK and ZAP70/BTK active kinase domains available for direct enzymatic comparison. Human/Mouse/Cyno SYK ortholog proteins with intact ATP-binding sites; >95% purity; Theoretical MW confirmed by SDS-PAGE. |
| Drug Resistance Screening | Sequence Verified clinical resistance mutant recombinant proteins available, including ATP-binding site mutant panel. Wild-type comparator included. |
| Lack of Positive Controls | Validated expression plasmids, lentivirus, and reference antibodies included for cellular and biochemical assays. |
| Cellular Context Assays | High-titer Lentivirus for stable overexpression in SYK-deficient cell lines (e.g., HEK293-SYK). |
| Compound Permeability | Cell-based validation using lentivirus-transduced lines with endogenous expression levels. |
| False Positives in Cell Assays | Validated siRNA set included for target-specific knockdown verification. |
Live SYK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for SYK inhibitors is shifting from broad immunosuppression toward selective B-cell and microglial targeting. With fostamatinib established in chronic immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), the field is pivoting toward neurological applications (multiple sclerosis, Alzheimer's) and oncology combinations. The next wave of R&D focuses on CNS-penetrant inhibitors, PROTAC-mediated degradation, and allosteric modulation to overcome residence time limitations and selectivity challenges against ZAP70 and BTK. As first-generation ATP-competitive inhibitors face hurdles, the demand for rigorous biochemical and cellular selectivity assays has intensified.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (ATP-competitive) | Rigel, Gilead, Takeda, Roche, Hutchison MediPharma | ITP, Rheumatoid Arthritis, AML, MS | Selectivity Assay (Need High-Purity WT and ZAP70/BTK Kinase Proteins) |
| PROTAC / Degrader | Kymera, Nurix, Various Biotechs | B-Cell Lymphomas | Degradation Assays (Need high-specificity SYK antibody and stable cell lines) |
| Allosteric Inhibitor | Various Biotech | Autoimmune | Conformation-specific binding (Need full-length SH2-containing protein) |
| Combination (SYK + BTK) | Multiple Sponsors | Refractory CLL/Mantle Cell Lymphoma | Pathway Validation (Need panels of BCR pathway kinases) |